Latest From Denstply Sirona
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.
There were 225 medtech M&A deals in 2015, down from 269 in 2014, according to Clinica's M&A Tracker. The in vitro diagnostics sector continues to be the most popular for transactions.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
AstraZeneca offloaded former Amgen-partnered IL-17 antagonist brodalumab to Valeant; there was consolidation in the dental instruments industry via the $5.3bn merger of Dentsply and Sirona. Compared with August, financing in the biopharma sector was up while device was flat.
- Consumables, Central Supplies
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Dental & Oral Products
- Dentsply International Inc.
- Sirona Dentsply
- North America
- Parent & Subsidiaries
- Denstply Sirona
- Senior Management
Donald M Casey, Jr., CEO
Jorge M Gomez, CFO
- Contact Info
Phone: (704) 587-0453
13320-B, Ballantyne Corporate Place
Charlotte, NC 28277
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.